Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr:2:140-146.
doi: 10.1016/j.coisb.2017.04.003. Epub 2017 Apr 27.

Treatable traits and therapeutic targets: Goals for systems biology in infectious disease

Affiliations
Review

Treatable traits and therapeutic targets: Goals for systems biology in infectious disease

Clark D Russell et al. Curr Opin Syst Biol. 2017 Apr.

Abstract

Among the many medical applications of systems biology, we contend that infectious disease is one of the most important and tractable targets. We take the view that the complexity of the immune system is an inevitable consequence of its evolution, and this complexity has frustrated reductionist efforts to develop host-directed therapies for infection. However, since hosts vary widely in susceptibility and tolerance to infection, host-directed therapies are likely to be effective, by altering the biology of a susceptible host to induce a response more similar to a host who survives. Such therapies should exert minimal selection pressure on organisms, thus greatly decreasing the probability of pathogen resistance developing. A systems medicine approach to infection has the potential to provide new solutions to old problems: to identify host traits that are potentially amenable to therapeutic intervention, and the host immune factors that could be targeted by host-directed therapies. Furthermore, undiscovered sub-groups with different responses to treatment are almost certain to exist among patients presenting with life-threatening infection, since this population is markedly clinically heterogeneous. A major driving force behind high-throughput clinical phenotyping studies is the aspiration that these subgroups, hitherto opaque to observation, may be observed in the data generated by new technologies. Subgroups of patients are unlikely to be static - serial clinical and biological phenotyping may reveal different trajectories through the pathophysiology of disease, in which different therapeutic approaches are required. We suggest there are two major goals for systems biology in infection medicine: (1) to identify subgroups of patients that share treatable features; and, (2) to integrate high-throughput data from clinical and in vitro sources in order to predict tractable therapeutic targets with the potential to alter disease trajectories for individual patients.

Keywords: Endotypes; Genomics; Infectious disease; Transcriptomics; Treatable traits.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of a systems medicine approach to infection. A wide range of data sources can be combined using various methods (see text) to achieve two fundamental goals – clinically-informative phenotyping of patients, and identification of therapeutic targets.
Figure 2
Figure 2
Hypothetical trajectories of two groups of patients through multidimensional space. Each line indicates the path taken by a single patient, with periods of organ failure highlighted in red. A superficially similar group of patients may appear clinically indistinguishable (a), but different trajectories through illness are revealed by informative vectors derived from high-throughput data (b). It is reasonable to expect that such biological differences in disease process will underlie different responses to host-directed therapies.

References

    1. Lawrie R. First clinical use of penicillin. Br Med J (Clin Res Ed) 1985;290:397. - PMC - PubMed
    1. Angus D.C., van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–851. - PubMed
    1. O'Neill J. vol. 2016. 2016. (Tackling drug-resistant infections globally: final report and recommendations). Edited by: Review on antimicrobial resistance.
    1. Cornelis G.R. The Yersinia Ysc-Yop 'type III' weaponry. Nat Rev Mol Cell Biol. 2002;3:742–752. - PubMed
    1. Simard M., Hill L.A., Underhill C.M., Keller B.O., Villanueva I., Hancock R.E., Hammond G.L. Pseudomonas aeruginosa elastase disrupts the cortisol-binding activity of corticosteroid-binding globulin. Endocrinology. 2014;155:2900–2908. - PMC - PubMed

LinkOut - more resources